Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment
Authors not listed
Groupe Oncologie Radiotherapie Tete et Cou · 2013
Abstract
The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty (after geriatric assessment).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
Anonymous. (2013). Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment. <em>Groupe Oncologie Radiotherapie Tete et Cou</em>. https://clinicaltrials.gov/study/NCT01864772
Vancouver
Anonymous. Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment. Groupe Oncologie Radiotherapie Tete et Cou. 2013.
BibTeX
@misc{anon2013PhaseI,
title = {Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment},
author = {Anonymous},
journal = {Groupe Oncologie Radiotherapie Tete et Cou},
year = {2013},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.